Search - tctmd.com

Displaying 21 - 40 of 125

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

JACC Statement Focuses on PAD Disparities, Gaps in Care

L.A. McKeown

December 04, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

L.A. McKeown

May 24, 2023

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

Advertisement

January 2024 Dispatch for the CV Team

Top Endovascular News of 2023

JACC Statement Focuses on PAD Disparities, Gaps in Care

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

Only Half of Revascularized PAD Patients Receive GDMT

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Top Endovascular News of 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

February 2022 News Roundup

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content